期刊文献+

替比夫定治疗乙型肝炎肝硬化失代偿疗效分析及对肾脏功能的影响 被引量:6

Efficacy of telbivudine in chronic hepatitis B patients with decompensated liver crirrhosis and its influence on renal function
下载PDF
导出
摘要 目的评价替比夫定治疗乙型肝炎肝硬化失代偿患者的疗效及对肾脏功能的影响。方法回顾性分析2012年4月至2015年11月在上海市松江区中心医院感染科就诊的失代偿期乙型肝炎肝硬化患者72例,给予替比夫定抗病毒治疗,在治疗后24周、48周观察血清丙氨酸氨基转移酶(ALT)、血清总胆红素(TBil)、白蛋白(Alb)、凝血酶原时间(PT)、Child-Pugh积分、腹水、HBV DNA、阴转率及耐药变异率;比较治疗后24周、48周血清肌酐(CR),估算肾小球滤过率(eGFR)较基线的变化情况。计量资料比较采用独立样本t检验,治疗前后比较采用配对t检验,计数资料采用x^2检验。结果治疗24周时,血清ALT、TBil、HBV DNA载量均值分别为:46.12 U/L、44.31μmol/L和1.89 lg拷贝/mL,HBV DNA阴转率为75.00%,均较治疗前有明显改善(P<0.05)。2例患者出现耐药变异,但未发现有腹水消失的病例;随着治疗时间延长至48周,Alb水平和PT均值分别为:34.16 g/L和1 5.09 s,Child-Pugh积分也较治疗前进一步明显改善(P<0.05),有3例患者腹水消失且耐药变异病例增加至5例。治疗48周时eGFR及CR分别为:108.48 mL/(min·1.73 m^2)和0.83 mg/dL,均较治疗前明显改善(P<(.05),39例基线肾功能轻度受损[eGFR 60~90 mL/(min·1.73 m^2)]患者中,有9例患者(23.08%)上升至eGFR≥90mL/(min·1.73 m^2)。结论替比夫定治疗乙型肝炎肝硬化失代偿期患者在有效抑制病毒及改善肝脏储备功能方面疗效肯定,随着治疗时间的延长治疗效果更加明显,但有部分患者出现耐药变异;替比夫定有改善肾脏功能的作用,对于基线肾功能受损的患者,其肾脏功能可得到一定程度的恢复。 Objective To investigate the efficacy of telbivudine (LDT) in patients with hepatitis B virus (HBV)- related decompensated liver cirrhosis and evaluate its influence on renal function. Methods In the retrospective analysis, 72 patients with HBV-related decompensated liver cirrhosis in our hospital from April 2012 to October 2015 received LDT (600 mg/d) antiviral therapy. The levels of alanine aminotransferase (ALT), total bilirubin (TBil), albumin (Alb), prothrombin time (PT) , ascites, Child-Pugh integral, HBV DNA load, HBV DNA undetectable rate and resistance mutation were evaluated at baseline, week 24 and 48. Serum creatinine (CR) and estimated of glomerular filtration rate (eGFR) were also monitored. Comparisons among baseline, week 24 and 48 were carried out by chisquare test and t-test. Results At week 24, mean levels of ALT, TBil, HBV DNA load and HBV DNA undetectable rate were 46. 12 U/L, 44. 31 mol/L,1. 89 lg copies/mL and 75. 00% , respectively. All results were significantly improved, as compared with those at baseline (P〈C0. 05). Meanwhile? resistance mutations occurred in 2 cases,and ascites regression had not been reported. At week 48, levels of Alb and PT were 34. 16 g/L and 15. 09 sec, and Child-Pugh integral was significantly decreased as compared to that at baseline (P〈0. 05). In addition, resistance mutations occurred in 5 cases,and ascites regression was found in 3 cases. Compared with those at baseline, CR level reduced to 0. 83 mg/dL and eGFR level raised to 108. 48 mL/(min · 1. 73 m^2 ) after 48-week treatment (P〈0. 05). Furthermore, 9 (23. 08%) patients with mild renal impairment improved with eGFR^90 mL/(min · 1. 73 m^2 ). Conclusion LDT is a crucial strategy for inhibiting virus replication and improving liver function in chronic hepatitis B patients with decompensated liver cirrhosis. Althoughprolonging treatment can enhance therapeutic efficacy, it also increases resistance mutations risk. In terms of patients with mild renal impairment, LDT might be an appropriate option for its improvement in renal function.
出处 《肝脏》 2016年第9期722-725,共4页 Chinese Hepatology
基金 上海市松江区计划和生育委员会重点项目(2012-Ⅲ-06)
关键词 替比夫定 乙型肝炎 肝硬化 疗效 肾脏功能 Telbivudine Chronic hepatitis B Liver cirrhosis Efficacy Renal function
  • 相关文献

参考文献4

二级参考文献59

  • 1殷思纯,翟洁卿,尹红,罗北京,华莉.肝硬化患者的肾功能改变[J].广东医学,2006,27(6):905-906. 被引量:8
  • 2[1]Lee WM.Hepatitis B virus infection.N Engl J Med 1997; 337:1733-1745
  • 3[2]Mohanty SR,Kupfer SS,Khiani V.Treatment of chronic hepatitis B.Nat Clin Pract Gastroenterol Hepatol 2006; 3:446-458
  • 4[3]Beasley RP.Hepatitis B virus.The major etiology of hepatocellular carcinoma.Cancer 1988; 61:1942-1956
  • 5[4]McMahon BJ,Holck P,Bulkow L,Snowball M.Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus.Ann Intern Med 2001; 135:759-768
  • 6[5]Parkin DM,Bray F,Ferlay J,Pisani P.Estimating the world cancer burden:Globocan 2000.Int J Cancer 2001; 94:153-156
  • 7[6]Fung SK,Lok AS.Drug insight:Nucleoside and nucleotide analog inhibitors for hepatitis B.Nat Clin Pract Gastroenterol Hepatol 2004; 1:90-97
  • 8[7]Chowdhury A.Epidemiology of hepatitis B virus infection in India.Hep B Annual 2004; 1:17-24
  • 9[8]Thyagrajan SP,Jayaram S,Hari R,Mohan KVK,Murugavel KG.Epidemiology of hepatitis B in India-A comprehensive analysis.In:Hepatitis B and C carrier to cancer.Sarin SK,Okuda K,editors.1st ed.New Delhi:Harcourt India Private Ltd,2002:25-39
  • 10[9]Tandon BN,Acharya SK,Tandon A.Epidemiology of hepatitis B virus infection in India.Gut 1996; 38 Suppl 2:S56-S59

共引文献94

同被引文献37

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部